A dose of the drug simvastatin results in cognitive improvement in people with secondary progressive multiple sclerosis (SPMS), according to research published in the Lancet Neurology.
Publication date: 7 June 2017
UCL Institute of Neurology researcher is leading a phase 3 trial involving more than 1,000
people with multiple sclerosis (MS) to investigate whether simvastatin
could become a treatment for the condition
Publication date: 9 May 2017
Launch of the PHAGO project to explore a new approach for patients suffering from Alzheimer’s disease
On 1st November 2016 the Innovative
Medicines Initiative (IMI) together with an association of industrial partners came
together to support PHAGO, an innovative research project devoted to the
development of immunomodulatory therapies for Alzheimer’s disease (AD).
Publication date: 11 January 2017
A trial has started of a treatment that mimics the properties of cannabis to help reduce spasticity associated with multiple sclerosis (MS). The trial is being led by Dr Rachel Farrell, a consultant at the National Hospital for Neurology and Neurosurgery (UCLH) and Honorary Senior Lecturer at the UCL Institute of Neurology.
Publication date: 11 December 2015
A neurotransmitter widely distributed in the brain may be a marker of a progressive multiple sclerosis, according to research led by Professor Olga Ciccarelli, UCL Institute of Neurology, published in Brain.
Publication date: 4 September 2015
Optic neuritis is an inflammatory optic neuropathy that is frequently- but not always - associated with multiple sclerosis (MS). Despite recent developments in laboratory, imaging and electrophysiological techniques, no consensus guidelines have yet been formulated for the diagnostic work-up in patients presenting with optic neuritis.
Publication date: 14 July 2014
Research published in the Lancet, led by Dr Jeremy Chataway (Honorary Senior Lecturer, UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery), has found that a high dose of the cholesterol-lowering drug simvastatin reduces the rate of brain shrinkage in people with secondary progressive multiple sclerosis (SPMS) by about 40% (the untreated rate is approximately 0.6% a year).
Publication date: 19 March 2014
Congratulations to Professor David Miller (Department of Neuroinflammation) who was the 2011 Raymond D Adams Memorial Lecturer at the Department of Neurology, Massachusetts General Hospital, Boston. He delivered this highly prestigious lecture, entitled “Imaging the evolution of multiple sclerosis”, on December 8th.
Publication date: 9 December 2011
Publication date: 6 May 2010
Roads were closed in central London on Saturday as a new high-powered, six tonne MRI scanner was installed at the UCL Institute of Neurology in Queen Square.
Publication date: 22 September 2009